During shortages of Wegovy, Ozempic, Mounjaro, and Zepbound, the FDA exercised temporary enforcement discretion , allowing compounding pharmacies to help meet patient demand. Once manufacturing stabilized: Semaglutide injection products were removed from the FDA Drug Shortage List Tirzepatide injection products were formally declared resolved Compounding reverted to pre-shortage federal and state limits Broad, shortage-based compounding is no longer allowed in 2026
Before After Not because of a crash diet or extreme plan, but because calm consistency changes everything
Potential long-term concerns include bone health, as some diabetes medications have been linked to a higher risk of fractures
Instead, drugs like tirzepatide and semaglutide create direct metabolic shiftsincluding increased fat oxidation and improved fuel partitioningregardless of appetite
These findings do not mean the drugs are damaging the thyroid in a predictable way
The product is intended strictly for laboratory research and scientific investigation